Clinical studies have shown a > 50% lower simvastatin (CYP3A4 substrate) exposure 1 week after a single anti-IL-6R dose in patients with rheumatoid arthritis [12, 13], indicating a normalization (increase) in CYP3A4 activity. Here, CYP3A4 is linked to rheumatoid arthritis.